PURIFY Investigators Announce First Patient Enrolled in a US Randomized Controlled IDE Trial Evaluating Seraph 100 for the Treatment of Septic Shock

  • Kevin Chung

Press/Media

Period2 Mar 2022

Media coverage

6

Media coverage